Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting

PharmacoEconomics

Volumn 31, Issue 10, 2013, Pages 909-918

  Kleintjens, Joris ^a   Li, Xiao ^a   Simoens, Steven ^b   Thijs, Vincent ^b,c,d   Goethals, Marnix ^e   Rietzschel, Ernst R ^f   Asukai, Yumi ^g   Saka, Ömer ^a   Evers, Thomas ^h   Faes, Petra ⁱ   Vansieleghem, Stefaan ⁱ   De Ruyck, Mimi ⁱ  

^a Health Economics and Outcomes Research   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e University Hospitals Leuven ^*  (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g IQVIA   (United States)

^h BAYER PHARMA AG   (Germany)

ⁱ Market Access Department   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; EMBOLISM; HEALTH CARE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BELGIUM; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MORPHOLINES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STROKE; THIOPHENES; WARFARIN;

EID: 84886035868     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0087-9     Document Type: Article

References (42)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561-4.
2. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115-9.
3. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182-7.
4. Mackay J, Menash GA, Greenlund K. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004.
5. Devroey D, Van Casteren V, Buntinx F. Registration of stroke through the Belgian sentinel network and factors influencing stroke mortality. Cerebrovasc Dis. 2003;16:272-9.
6. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibriliation. The Task Force for the Management of Atrial Fibrilation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
7. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol. 1998;101:374-87.
8. Bayer HealthCare. Data on file: Cegedim report 2010.
9. Evers T, O'Neil WM, Ogilvie IM, et al. PCV144 - Stroke prevention in patients with atrial fibrillation: inappropriate anticoagulation and poor INR control. Value Health. 2011;14:A390.
10. Ansell J, Hirsch J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(suppl):S160-98.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
12. Stuart J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
13. Granger B, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
14. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-47.
15. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7.
16. Sanchez MM, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med. 2006;25:1169-81.
17. US Department of Health and Human Services. Guidance for industry: non-inferiority clinical trials (draft guidance). Center for Biologics Evaluation and Research (CBER), 2010.
18. Briggs AHE, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
19. Federal Public Service Economy, SMEs, Self-Employed and Energy. Life tables Belgium 1998-2009. [Online]. http://statbel.fgov.be/nl/modules/ publications/statistiques/bevolking/downloads/bevolking-sterftetafels.jsp. Accessed 8 Jan 2013.
20. Hoit BD, Gilpin EA, Henninh H, et al. Myocardial infarction in young patients: an analysis by age subsets. Circulation. 1986;74:712-21.
21. Gailly J, Gerkens S, Van Den Bruel A, et al. Use of point-of care devices in patients with oral anticoagulation: a Health Technology Assessment. Belgian Health Care Knowledge Centre. Report number: 117C, 2009.
22. Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmacoeconomic evaluations in Belgium. Belgian Health Care Knowledge Centre. Report number: 78C, 2008.
23. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380-4.
24. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-36.
25. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: NICE technology appraisal guidance 256. Report number: TA256, 2012.
26. Lee S, Anglade MW, Pisacane R, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845-51.
27. Wouters et al. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. Epub 2013 Jan 22
28. HAS, Department of Medecines Assessment. Indirect comparisons methods and validity [Online] Available from: www.has-sante.fr. 2009; July:35.
29. Limone et al. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLOS One. 2013;8(4):e62183.
30. Claes N. Quality of oral anticoagulation in patients with atrial fibrillation: a cross-sectional study in general practice. Eur J Gen Pract. 2006;12:163-8.
31. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med. 2003;349:1019-26.
32. Bayer Plc. Submission to National Institute for Health and Clinical Excellence: Single Technology Appraisal (STA) of Rivaroxaban (Xarelto®). 2011.
33. RIZIV/INAMI. Nomenclature codes 101010, 101032, 101076, 103110, 103132, 592815, 592830, 554573. [Online]. http://www.inami.fgov.be/homefr.htm. Accessed August 2011.
34. RIZIV/INAMI. APR DRG codes 045 and 813 - nomenclature codes 460821, 591603, 598021, 598043, 598146, 700000 766065, 766264, and 799621. [Online]. Available from: http://www.inami.fgov.be/homefr.htm. Accessed August 2011.
35. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49:572-7.
36. Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy. 2001;6:92-8.
37. Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med. 1999;246:309-16.
38. Sullivan PW, Arant TW, Ellis SL, et al. The cost-effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk for stroke in the US. Pharmacoeconomics. 2006;24:1021-33.
39. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49-56.
40. Haacke C, Althaus A, Spottke A, et al. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006;37:193-8.
41. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870-83.
42. Robinson MB, Thompson E, Black NA. A model for estimating the cost-utility of clinical audit. The example of thrombolysis for suspected acute myocardial infarction. Int J Technol Assess Health Care. 1998;14:161-71.